What happens to older adults who stop a statin they take just for prevention?
Nothing measurably bad, at least over three years. In this French trial of 1,160 adults aged 75 and older, 7.2% of those who stopped their statin died within three years, compared with 7.9% of those who kept taking it.
Every one of these people was taking a statin for what doctors call primary prevention. That means they had never had a heart attack, a stroke, or any other blockage-related artery disease. They were on the drug to stop a first event from ever happening, not to protect a heart that had already been damaged.
That distinction matters, because the evidence for statins in people over 75 who have never had an event has always been thin. The authors of this trial say so plainly: whether a statin taken for prevention still helps at 75 or older remains uncertain. This trial set out to answer that question directly.
What the data show
At three years, 48 of 604 people who continued their statin had died, which is 7.9%. Among those who stopped, 35 of 484 had died, or 7.2%. The absolute difference was 0.68% in favor of stopping, which works out to roughly 7 fewer deaths per 1,000 people over three years in the group that quit.
That difference is far too small to mean anything on its own. The useful part is the range around it. The researchers reported a confidence interval of minus 3.95% to plus 2.60%, which in plain terms means the true effect is very likely somewhere between about 40 fewer deaths per 1,000 and about 26 more deaths per 1,000 over three years. Before the trial started, the team had set 5% as the line that would count as real harm. The range never came close to crossing it. That is what “non-inferior” means here: stopping did not cost these patients measurable survival.
Side effects landed in the same place. Adverse events occurred in 73.1% of the continuation group and 74.0% of the discontinuation group, a difference of under one percentage point. Non-cardiovascular adverse events were 72.3% versus 72.7%. Stopping the drug did not make people noticeably healthier in the short run either.
Dr. Kumar’s Take
I prescribe statins, and I still think they are one of the most valuable drugs in medicine. This trial does not change that. What it changes is the reflex.
Older patients accumulate medications the way a garage accumulates boxes. Nobody remembers who put the statin there or why, and nobody wants to be the one who removes it. This trial gives me randomized evidence that for a specific, well-defined patient, taking the box out is a reasonable option rather than a gamble.
The patient this applies to is narrow. No heart attack. No stroke. No known blockage disease anywhere. Already 75 or older. If any of those is untrue, the calculation is completely different, and stopping a statin after a heart attack or stroke is a decision with real evidence against it.
Three years of follow-up is also short for a drug that works slowly over decades. A 76 year old who stops today and lives another 18 years was not represented by this trial. What the trial can tell you is that the first three years look safe, which is exactly the window most patients and families are worried about.
How the trial was run
Researchers recruited from 297 primary care offices across France between June 2016 and January 2020. To qualify, a person had to be 75 or older and to have been taking a statin for at least a year for prevention only. People with dementia, with a life expectancy of three months or less, or with inherited severe cholesterol disorders were excluded. Participants were then randomly assigned to keep taking the statin or to stop, in a 5 to 4 split, and followed for 36 months.
The median age was 80, with half the group between 78 and 84. Two thirds were women. Nearly a third had diabetes and more than three quarters had high blood pressure, so this was not an unusually healthy group of older people.
Safety, limits, and caveats
Nobody was blinded. Patients knew whether they had stopped, and so did their doctors, which can shape follow-up care and reporting. The trial was also built around one primary question, death from any cause, and it was sized to answer that question rather than to detect smaller shifts in specific outcomes.
The result also depends on the population being what it says it is. “No history of atherosclerotic cardiovascular disease” is a clean line on paper and a blurrier one in a real clinic, where an older patient may have silent disease nobody has looked for. The authors are explicit that their findings support individualized decisions, not a blanket rule.
Practical takeaways
- If you are over 75 and take a statin, find out first whether you take it because of a past heart attack or stroke, or purely as prevention, because this trial only speaks to the second group.
- Do not stop a statin on your own after reading a headline, since the trial randomized the decision with a doctor involved and monitored people for three years.
- Bring this trial up at your next visit if you are on a long medication list, because it gives your doctor randomized evidence to work with rather than a hunch.
- Remember that a statin was never the only lever, and blood pressure control, activity, and smoking status all still matter regardless of what you decide about the pill.
Related Studies and Research
- Do statins really help prevent heart disease? A closer look at the evidence
- Does rosuvastatin prevent heart disease in healthy people with intermediate risk? A look at the HOPE-3 trial
- Shingles vaccine cuts heart attack risk nearly in half for heart disease patients
- Treating gout properly may cut heart attack and stroke risk by up to 23%
FAQs
Does this mean statins do not work in people over 75?
No. The trial did not test whether statins prevent heart attacks in older adults who never took them. It tested what happens when people already on a statin for prevention stop. Those are different questions. A drug can lower cholesterol and still add little to survival in someone whose competing risks over the next three years are dominated by other conditions.
Why did the researchers use survival rather than heart attacks as the main outcome?
All-cause mortality is the hardest outcome to fudge. It does not depend on who got scanned, who got admitted, or how a symptom was coded. In an open-label trial where nobody is blinded, that matters even more, because softer outcomes can drift based on what patients and doctors expect. The tradeoff is that death from any cause is a blunt measure, and it can hide a shift in one specific type of event.
What should someone with a past heart attack or stroke take from this?
Very little that applies to them directly. Everyone in this trial had no history of blockage-related artery disease, and that was an entry requirement, not an incidental detail. For people who have already had an event, the evidence for staying on a statin is much stronger and comes from large trials designed to answer that exact question.
Is three years long enough to call stopping safe?
It is long enough to say that the first three years carry no measurable survival cost in this group, and that is a real answer to a real question. It is not long enough to speak to someone who might live another 15 or 20 years. The longer the remaining life expectancy, the more the usual reasoning about slow-acting preventive drugs applies again.
Bottom Line
In 1,160 adults aged 75 and older who were taking a statin purely to prevent a first cardiovascular event, stopping the drug was not worse than continuing it for survival over three years. Deaths were 7.2% in the group that stopped and 7.9% in the group that continued, and side effect rates were nearly identical. This is not permission to throw out the bottle. It is permission to have the conversation, with the person who knows your history, about whether the pill is still earning its place.
